

DEUTSCHE BANK AKTIENGESELLSCHAFT
Form 424B2
April 17, 2018

Pricing Supplement No. 3074

*To prospectus supplement dated July 31, 2015 and
prospectus dated April 27, 2016*

Registration Statement No. 333-206013

Rule 424(b)(2)

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus supplement and prospectus do not constitute an offer to sell nor do they seek an offer to buy the notes in any jurisdiction where the offer or sale is not permitted.

Subject to Completion. Dated April 17, 2018

Deutsche Bank AG

\$ Cash-Settled Equity-Linked Notes Linked to the Common Stock of JPMorgan Chase & Co. due May 1, 2023

General

The notes (the “**notes**”) are designed for investors who seek exposure to the potential appreciation, if any, of the common stock of JPMorgan Chase & Co. (the “**Reference Stock**”). The notes will pay interest semi-annually at % per annum.

The notes may not be exchanged by you or redeemed by us prior to the Maturity Date. Investors will receive at maturity a cash payment *plus* any accrued but unpaid interest. The payment at maturity will be calculated based on the Final Price of the Reference Stock over 5 Valuation Dates as described below, with each Valuation Date determining 1/5th of the final payment. The payment at maturity is expected to be greater than or equal to the Face Amount per \$1,000 Face Amount of notes. Because the original Issue Price per \$1,000 Face Amount of notes is 105.00% of the Face Amount, you will lose approximately 4.76% of your investment if you receive the Face Amount per \$1,000 Face Amount of notes at maturity. Excluding interest payments, the notes will not provide for any positive return if the Final Price on each Valuation Date is equal to or less than 105.00% of the Threshold Price. *Any payment on the notes is subject to the credit of the Issuer.*

Senior unsecured obligations of Deutsche Bank AG due May 1, 2023

Minimum purchase of \$100,000. Minimum denominations of \$1,000 (the “**Face Amount**”) and integral multiples of \$1,000 in excess thereof.

The notes are expected to price on or about April 18, 2018 (the “**Pricing Date**”) and are expected to settle on or about April 23, 2018 (the “**Settlement Date**”).

Key Terms

Issuer: Deutsche Bank AG, London Branch

Issue Price: 105.00% of the Face Amount

Reference Stock: The common stock of JPMorgan Chase & Co. (Bloomberg ticker: JPM).

Interest Rate: % per annum. The notes will pay interest on a semi-annual basis in arrears at the Interest Rate on each Interest Payment Date, including the Maturity Date, based on a 30/360 adjusted day count convention.

Interest Payment Dates¹: The 1st of May and November, beginning on November 1, 2018 and ending on the Maturity Date.

Payment at Maturity: You will receive on the Maturity Date a cash payment per \$1,000 Face Amount of notes equal to the sum of the Daily Values for each of the 5 Valuation Dates *plus* any accrued but unpaid interest. *Because the Issue Price is 105.00% of the Face Amount, you will lose up to approximately 4.76% of your investment if the Final Price on each Valuation Date is less than 105.00% of the Threshold Price.*

Daily Values: For each Valuation Date, the greater of (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

Alternative Settlement Amount: For each Valuation Date, an amount calculated as follows:

Threshold Price: $\$200 \times (\text{Final Price on that Valuation Date} / \text{Threshold Price})$

Initial Price: % of the Initial Price

Final Price: The Adjusted VWAP of one share of the Reference Stock on the trading day immediately following the Pricing Date, as determined in the sole discretion of the calculation agent. **The Initial Price will likely differ from the Adjusted VWAP and the regular official weekday closing price of one share of the Reference Stock on the Pricing Date.** The calculation agent is under no obligation to consider your interests as a holder of the notes in taking any actions, including the determination of the Initial Price, that might affect the value of your notes.

Final Price: With respect to each Valuation Date, the Adjusted VWAP on that Valuation Date

(Key Terms continued on next page)

Investing in the notes involves a number of risks. See “Risk Factors” beginning on page PS-5 of the accompanying prospectus supplement and page 13 of the accompanying prospectus and “Selected Risk Considerations” beginning on page PS-11 of this pricing supplement.

The Issuer’s estimated value of the notes on the Pricing Date is approximately \$1,044.75 to \$1,048.95 per \$1,000 Face Amount of notes, which is less than the Issue Price. Please see “Issuer’s Estimated Value of the Notes” on page PS-4 of this pricing supplement for additional information.

By acquiring the notes, you will be bound by and deemed irrevocably to consent to the imposition of any Resolution Measure (as defined below) by the competent resolution authority, which may include the write down of all, or a portion, of any payment on the notes or the conversion of the notes into ordinary shares or other instruments of ownership. If any Resolution Measure becomes applicable to us, you may lose some or all of your investment in the notes. Please see “Resolution Measures and Deemed Agreement” on page PS-5 of this pricing supplement for more information.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this pricing supplement or the accompanying prospectus supplement or prospectus. Any representation to the contrary is a criminal offense.

	Price to Public	Discounts and Commissions⁽¹⁾	Proceeds to Us
Per Note	\$1,050.00	\$0.00	\$1,050.00
Total	\$	\$	\$

Deutsche Bank Securities Inc. (“**DBSI**”), acting as agent for Deutsche Bank AG, will not receive a selling concession ⁽¹⁾in connection with the sale of the notes. For more detailed information about discounts, commissions and fees, please see “Supplemental Plan of Distribution (Conflicts of Interest)” in this pricing supplement.

The agent for this offering is our affiliate. For more information, please see “Supplemental Plan of Distribution (Conflicts of Interest)” in this pricing supplement.

The notes are not deposits or savings accounts and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other U.S. or foreign governmental agency or instrumentality.

Deutsche Bank Securities Inc.

April , 2018

(Key Terms continued from previous page)

Adjusted VWAP:	For any relevant trading day, the VWAP on such trading day <i>multiplied</i> by the then-current Stock Adjustment Factor
VWAP:	For any relevant trading day, the volume-weighted average of the Reference Stock on such trading day as defined under “Description of the Notes — Definitions” in this pricing supplement
Stock Adjustment Factor:	Initially 1.0, subject to adjustment upon the occurrence of certain corporate events affecting the Reference Stock. See “Description of the Notes — Anti-Dilution Adjustments” in this pricing supplement.
Ordinary Dividend:	The regular quarterly cash dividend per one share of the Reference Stock paid by the issuer of the Reference Stock (the “ Reference Stock Issuer ”), as determined by the calculation agent
Base Dividend:	From the Settlement Date to the Maturity Date, \$0.56 per calendar quarter per share of the Reference Stock for the first Ordinary Dividend in such calendar quarter, and \$0.00 for all other dividends. The Base Dividend is used to calculate any adjustments to the Stock Adjustment Factor for cash dividends. See “Description of the Notes — Anti-Dilution Adjustments” in this pricing supplement.
Pricing Date:	April 18, 2018 (expected)
Settlement Date:	April 23, 2018 (expected)
Valuation Date ¹ :	Each of the 5 consecutive trading days beginning on, and including, the 7 th scheduled trading day immediately preceding the Maturity Date.
Maturity Date ¹ :	May 1, 2023
Listing:	The notes will not be listed on any securities exchange.
CUSIP / ISIN:	/

¹ Subject to adjustment as described under “Description of the Notes — Adjustments to Valuation Dates and Maturity Date” in this pricing supplement.

Issuer's Estimated Value of the Notes

The Issuer's estimated value of the notes is equal to the sum of our valuations of the following two components of the notes: (i) a bond and (ii) an embedded derivative(s). The value of the bond component of the notes is calculated based on the present value of the stream of cash payments associated with a conventional bond with a principal amount equal to the Face Amount of notes, discounted at an internal funding rate, which is determined primarily based on our market-based yield curve, adjusted to account for our funding needs and objectives for the period matching the term of the notes. The internal funding rate is typically lower than the rate we would pay when we issue conventional debt securities on equivalent terms. This difference in funding rate, as well as the agent's commissions, if any, and the estimated cost of hedging our obligations under the notes, reduces the economic terms of the notes to you and is expected to adversely affect the price at which you may be able to sell the notes in any secondary market. The value of the embedded derivative(s) is calculated based on our internal pricing models using relevant parameter inputs such as expected interest and dividend rates and mid-market levels of price and volatility of the assets underlying the notes or any futures, options or swaps related to such underlying assets. Our internal pricing models are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect.

The Issuer's estimated value of the notes on the Pricing Date (as disclosed on the cover of this pricing supplement) is less than the Issue Price of the notes. The difference between the Issue Price and the Issuer's estimated value of the notes on the Pricing Date is due to the inclusion in the Issue Price of the agent's commissions, if any, and the cost of hedging our obligations under the notes through one or more of our affiliates. Such hedging cost includes our or our affiliates' expected cost of providing such hedge, as well as the profit we or our affiliates expect to realize in consideration for assuming the risks inherent in providing such hedge.

The Issuer's estimated value of the notes on the Pricing Date does not represent the price at which we or any of our affiliates would be willing to purchase your notes in the secondary market at any time. Assuming no changes in market conditions or our creditworthiness and other relevant factors, the price, if any, at which we or our affiliates would be willing to purchase the notes from you in secondary market transactions, if at all, would generally be lower than both the Issue Price and the Issuer's estimated value of the notes on the Pricing Date. Our purchase price, if any, in secondary market transactions will be based on the estimated value of the notes determined by reference to (i) the then-prevailing internal funding rate (adjusted by a spread) or another appropriate measure of our cost of funds and (ii) our pricing models at that time, less a bid spread determined after taking into account the size of the repurchase, the nature of the assets underlying the notes and then-prevailing market conditions. The price we report to financial reporting services would generally be determined on the same basis.

Resolution Measures and Deemed Agreement

On May 15, 2014, the European Parliament and the Council of the European Union adopted a directive establishing a framework for the recovery and resolution of credit institutions and investment firms (commonly referred to as the “**Bank Recovery and Resolution Directive**”). The Bank Recovery and Resolution Directive required each member state of the European Union to adopt and publish by December 31, 2014 the laws, regulations and administrative provisions necessary to comply with the Bank Recovery and Resolution Directive. Germany adopted the Recovery and Resolution Act (*Sanierungs- und Abwicklungsgesetz*, or the “**Resolution Act**”), which became effective on January 1, 2015. The Bank Recovery and Resolution Directive and the Resolution Act provided national resolution authorities with a set of resolution powers to intervene in the event that a bank is failing or likely to fail and certain other conditions are met. From January 1, 2016, the power to initiate resolution measures applicable to significant banking groups (such as Deutsche Bank Group) in the European Banking Union has been transferred to the European Single Resolution Board which, based on the European Union regulation establishing uniform rules and a uniform procedure for the resolution of credit institutions and certain investment firms in the framework of a Single Resolution Mechanism and a Single Resolution Fund (the “**SRM Regulation**”), works in close cooperation with the European Central Bank, the European Commission and the national resolution authorities. Pursuant to the SRM Regulation, the Resolution Act and other applicable rules and regulations, the notes may be subject to any Resolution Measure by the competent resolution authority if we become, or are deemed by the competent supervisory authority to have become, “non-viable” (as defined under the then applicable law) and are unable to continue our regulated banking activities without a Resolution Measure becoming applicable to us. By acquiring the notes, you will be bound by and deemed irrevocably to consent to the provisions set forth in the accompanying prospectus, which we have summarized below.

By acquiring the notes, you will be bound by and deemed irrevocably to consent to the imposition of any Resolution Measure by the competent resolution authority. Under the relevant resolution laws and regulations as applicable to us from time to time, the notes may be subject to the powers exercised by the competent resolution authority to: (i) write down, including to zero, any payment (or delivery obligations) on the notes; (ii) convert the notes into ordinary shares of (a) the Issuer, (b) any group entity or (c) any bridge bank or other instruments of ownership of such entities qualifying as common equity tier 1 capital; and/or (iii) apply any other resolution measure including, but not limited to, any transfer of the notes to another entity, the amendment, modification or variation of the terms and conditions of the notes or the cancellation of the notes. We refer to each of these measures as a “**Resolution Measure**.” A “group entity” refers to an entity that is included in the corporate group subject to a Resolution Measure. A “bridge bank” refers to a newly chartered German bank that would receive some or all of our assets, liabilities and material contracts, including those attributable to our branches and subsidiaries, in a resolution proceeding.

Furthermore, by acquiring the notes, you:

are deemed irrevocably to have agreed, and you will agree: (i) to be bound by, to acknowledge and to accept any Resolution Measure and any amendment, modification or variation of the terms and conditions of the notes to give effect to any Resolution Measure; (ii) that you will have no claim or other right against us arising out of any Resolution Measure; and (iii) that the imposition of any Resolution Measure will not constitute a default or an event of default under the notes, under the senior indenture dated November 22, 2006 among us, Law Debenture Trust

Company of New York, as trustee, and Deutsche Bank Trust Company Americas, as issuing agent, paying agent, authenticating agent and registrar, as amended and supplemented from time to time (the “**indenture**”), or for the purposes of, but only to the fullest extent permitted by, the Trust Indenture Act of 1939, as amended (the “**Trust Indenture Act**”);

waive, to the fullest extent permitted by the Trust Indenture Act and applicable law, any and all claims against the trustee and the paying agent, the issuing agent and the registrar (each, an “**indenture agent**”) for, agree not to initiate a suit against the trustee or the indenture agents in respect of, and agree that the trustee and the indenture agents will not be liable for, any action that the trustee or the indenture agents take, or abstain from taking, in either case in accordance with the imposition of a Resolution Measure by the competent resolution authority with respect to the notes; and

will be deemed irrevocably to have: (i) consented to the imposition of any Resolution Measure as it may be imposed without any prior notice by the competent resolution authority of its decision to exercise such power with respect to the notes; (ii) authorized, directed and requested DTC and any direct participant in DTC or other intermediary through which you hold such notes to take any and all necessary action, if required, to implement the imposition of any Resolution Measure with respect to the notes as it may be imposed, without any further action or direction on your part or on the part of the trustee or the indenture agents; and (iii) acknowledged and accepted that the Resolution Measure provisions described herein and in the “Resolution Measures” section of the

PS-4

accompanying prospectus are exhaustive on the matters described herein and therein to the exclusion of any other agreements, arrangements or understandings between you and the Issuer relating to the terms and conditions of the notes.

This is only a summary, for more information please see the accompanying prospectus dated April 27, 2016, including the risk factors beginning on page 13 of such prospectus.

PS-5

Additional Terms Specific to the Notes

You should read this pricing supplement together with the prospectus supplement dated July 31, 2015 relating to our Series A global notes of which these notes are a part and the prospectus dated April 27, 2016. Delaware Trust Company, which acquired the corporate trust business of Law Debenture Trust Company of New York, is the successor trustee of the notes. When you read the accompanying prospectus supplement, please note that all references in such supplement to the prospectus dated July 31, 2015, or to any sections therein, should refer instead to the accompanying prospectus dated April 27, 2016 or to the corresponding sections of such prospectus, as applicable, unless otherwise specified or the context otherwise requires. You may access these documents on the website of the Securities and Exchange Commission (the “SEC”) at www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):

Prospectus supplement dated July 31, 2015:

http://www.sec.gov/Archives/edgar/data/1159508/000095010315006048/crt-dp58161_424b2.pdf

Prospectus dated April 27, 2016:

<http://www.sec.gov/Archives/edgar/data/1159508/000119312516559607/d181910d424b21.pdf>

Our Central Index Key, or CIK, on the SEC website is 0001159508. As used in this pricing supplement, “we,” “us” or “our” refers to Deutsche Bank AG, including, as the context requires, acting through one of its branches. This pricing supplement, together with the documents listed above, contains the terms of the notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in this pricing supplement and in “Risk Factors” in the accompanying prospectus supplement and prospectus, as the notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before deciding to invest in the notes.

You may revoke your offer to purchase the notes at any time prior to the time at which we accept such offer by notifying the applicable agent. We reserve the right to change the terms of, or reject any offer to purchase, the notes prior to their issuance. We will notify you in the event of any changes to the terms of the notes and you will be asked to accept such changes in connection with your purchase of any notes. You may choose to reject such changes, in which case we may reject your offer to purchase the notes.

Hypothetical Examples

The table and hypothetical examples set forth below assume an Initial Price of \$110, a Threshold Price of \$124.30 (equal to 113% of the hypothetical Initial Price) and that the Final Price for each of the 5 Valuation Dates is as specified below. Because the Initial Price will be the Adjusted VWAP of one share of the Reference Stock on the trading day immediately following the Pricing Date, the Initial Price and Threshold Price will not be determined until after that trading day. The tables and hypothetical examples set forth below are for illustrative purposes only. The actual returns applicable to a purchaser of the notes will depend on the Final Price of the Reference Stock on each Valuation Date. **The payment at maturity (excluding accrued but unpaid interest) will be determined over 5 Valuation Dates, with each Valuation Date determining 1/5th of such payment. Because the Issue Price is 105.00% of the Face Amount, you will lose up to approximately 4.76% of your investment if the Final Price on each Valuation Date is less than 105.00% of the Threshold Price.** You should consider carefully whether the notes are suitable to your investment goals. The numbers appearing in the tables and hypothetical examples below may have been rounded for ease of analysis, and it has been assumed that no event affecting the Reference Stock has occurred during the term of the notes that would cause the calculation agent to adjust the Stock Adjustment Factor.

The following table and hypothetical examples illustrate how the payment at maturity, excluding accrued but unpaid interest, is calculated.

Final Price on All Valuation Dates	Percentage Change from Initial Price to Final Price	Payment at Maturity	Total Return (based on the Issue Price of 105% of the Face Amount)
\$209.00	90.00%	\$1,681.42	60.13%
\$198.00	80.00%	\$1,592.92	51.71%
\$187.00	70.00%	\$1,504.42	43.28%
\$176.00	60.00%	\$1,415.93	34.85%
\$165.00	50.00%	\$1,327.43	26.42%
\$154.00	40.00%	\$1,238.94	17.99%
\$143.00	30.00%	\$1,150.44	9.57%
\$132.00	20.00%	\$1,061.95	1.14%
\$130.52	18.65%	\$1,050.00	0.00%
\$124.30	13.00%	\$1,000.00	-4.76%
\$121.00	10.00%	\$1,000.00	-4.76%
\$115.50	5.00%	\$1,000.00	-4.76%
\$110.00	0.00%	\$1,000.00	-4.76%
\$99.00	-10.00%	\$1,000.00	-4.76%

Edgar Filing: DEUTSCHE BANK AKTIENGESELLSCHAFT - Form 424B2

\$88.00	-20.00%	\$1,000.00	-4.76%
\$77.00	-30.00%	\$1,000.00	-4.76%
\$66.00	-40.00%	\$1,000.00	-4.76%
\$55.00	-50.00%	\$1,000.00	-4.76%
\$44.00	-60.00%	\$1,000.00	-4.76%
\$33.00	-70.00%	\$1,000.00	-4.76%
\$22.00	-80.00%	\$1,000.00	-4.76%
\$11.00	-90.00%	\$1,000.00	-4.76%
\$0.00	-100.00%	\$1,000.00	-4.76%

Example 1: The price of the Reference Stock increases 10% from the Initial Price of \$110 to the Final Price of \$121. Because the Final Price is \$121 on each Valuation Date, the Daily Value for each Valuation Date is calculated as follows:

PS-7

Daily Value for each Valuation Date = the *greater of* (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

= the *greater of* (i) \$200 and (ii) $\$200 \times (\$121 / \$124.30)$

= the *greater of* (i) \$200 and (ii) \$194.6903

Because the Alternative Settlement Amount for each Valuation Date is less than \$200, the Daily Value for each Valuation Date is \$200. Consequently, the payment at maturity, which will be equal to the sum of the Daily Values for each of the 5 Valuation Dates, is calculated as follows:

Payment at maturity = $\$200 \times 5 = \$1,000$

Thus, the payment at maturity will be only \$1,000 per \$1,000 Face Amount of notes even though the Reference Stock has increased 20% from the Initial Price to the Final Price. Because the payment at maturity is less than \$1,050 (which is the Issue Price of 105.00% of the Face Amount per \$1,000 Face Amount of notes), the total return of your initial investment, excluding interest payments, is -4.76%.

Example 2: The price of the Reference Stock decreases 20% from the Initial Price of \$110 to the Final Price of \$88. Because the Final Price is \$88 on each Valuation Date, the Daily Value for each Valuation Date is calculated as follows:

Daily Value for each Valuation Date = the *greater of* (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

= the *greater of* (i) \$200 and (ii) $\$200 \times (\$88 / \$124.30)$

= the *greater of* (i) \$200 and (ii) \$141.5929

Because the Alternative Settlement Amount for each Valuation Date is less than \$200, the Daily Value for each Valuation Date is \$200. Consequently, the payment at maturity, which will be equal to the sum of the Daily Values for each of the 5 Valuation Dates, is calculated as follows:

$$\text{Payment at maturity} = \$200 \times 5 = \$1,000$$

Thus, the payment at maturity will be \$1,000 per \$1,000 Face Amount of notes. Because the payment at maturity is less than \$1,050 (which is the Issue Price of 105.00% of the Face Amount per \$1,000 Face Amount of notes), the total return of your initial investment, excluding interest payments, is -4.76%.

Example 3: The price of the Reference Stock increases 80% from the Initial Price of \$110 to the Final Price of \$198. Because the Final Price is \$198 on each Valuation Date, the Daily Value for each Valuation Date is calculated as follows:

Daily Value for each Valuation Date = the *greater of* (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

$$= \text{the } \textit{greater of} \text{ (i) } \$200 \text{ and (ii) } \$200 \times (\$198 / \$124.30)$$

$$= \text{the } \textit{greater of} \text{ (i) } \$200 \text{ and (ii) } \$318.5841$$

Because the Alternative Settlement Amount for each Valuation Date is greater than \$200, the Daily Value for each Valuation Date is \$318.5841. Consequently, the payment at maturity, which will be equal to the sum of the Daily Values for each of the 5 Valuation Dates, is calculated as follows:

$$\text{Payment at maturity} = \$318.5841 \times 5 = \$1,592.92$$

Thus, the payment at maturity will be \$1,592.92 per \$1,000 Face Amount of notes even though the Reference Stock has increased 80% from the Initial Price to the Final Price. Because the payment is greater than \$1,050 (which is the Issue Price of 105.00% of the Face Amount per \$1,000 Face Amount of notes), the total return of your initial investment, excluding interest payments, is 51.71%.

PS-8

Example 4: The price of the Reference Stock increases from the Initial Price of \$110 to a Final Price of \$198 on the first 3 Valuation Dates and then decreases from \$198 to a Final Price of \$88 on the remaining 2 Valuation Dates. Because the Final Price is \$198 on the first 3 Valuation Dates and \$88 on the remaining 2 Valuation Dates, the Daily Value for each Valuation Date is calculated as follows:

Daily Value for each of the first 3 Valuation Dates = the *greater of* (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

= the *greater of* (i) \$200 and (ii) $\$200 \times (\$198 / \$124.30)$

= the *greater of* (i) \$200 and (ii) \$318.5841

Daily Value for each of the remaining 2 Valuation Dates = the *greater of* (i) \$200 and (ii) the Alternative Settlement Amount for that Valuation Date

= the *greater of* (i) \$200 and (ii) $\$200 \times (\$88 / \$124.30)$

= the *greater of* (i) \$200 and (ii) \$141.5929

Because the Alternative Settlement Amount for each of the first 3 Valuation Dates with a Final Price of \$198 is greater than \$200, the Daily Value for each of those Valuation Dates is \$318.5841. Because the Alternative Settlement Amount for each of the remaining 2 Valuation Dates with a Final Price of \$88 is less than \$200, the Daily Value for each of those Valuation Dates is \$200. The sum of the Daily Values for the first 3 Valuation Dates with a Final Price of \$198 is \$955.75, and the sum of the Daily Values for the 2 Valuation Dates with a Final Price of \$88 is \$400. Consequently, the payment at maturity, which will be equal to the sum of the Daily Values for each of the 5 Valuation Dates, is calculated as follows:

Payment at maturity = $\$318.5841 \times 3 + \200×2

= \$1,355.75

Thus, the payment at maturity will be \$1,355.75 per \$1,000 Face Amount of notes even though the Reference Stock has appreciated by 80% from the Initial Price to the Final Price for 3 of the Valuation Dates. Because the payment is greater than \$1,050 (which is the Issue Price of 105.00% of the Face Amount per \$1,000 Face Amount of notes), the total return of your initial investment, excluding interest payments, is 29.12%.

The hypothetical payments on the notes shown above apply **only if you hold the notes for their entire term**. These hypotheticals do not reflect fees or expenses that would be associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns and hypothetical payments shown above would likely be lower.

Selected Purchase Considerations

PARTIAL PRESERVATION OF CAPITAL AT MATURITY — We will pay you at least the Face Amount per \$1,000 Face Amount of notes if you hold the notes to maturity, regardless of the performance of the Reference Stock. Because the Issue Price per \$1,000 Face Amount of notes is 105.00% of the Face Amount and you are not protected on amounts in excess of the \$1,000 Face Amount, you may lose up to approximately 4.76% of your investment at maturity. **Any payment on the notes is subject to our ability to satisfy our obligations as they become due.**

APPRECIATION POTENTIAL — The payment at maturity will be calculated over 5 Valuation Dates, with each Valuation Date determining 1/5th of the final payment at maturity. If you hold the notes to maturity, you will receive a cash payment at maturity that is more than the Face Amount per \$1,000 Face Amount of notes (excluding accrued but unpaid interest) only if the Final Price on at least one Valuation Date is greater than the Threshold Price. However, because the Issue Price is 105.00% of the Face Amount, excluding interest payments, the notes will not provide for any positive return if the Final Price on each Valuation Date is equal to or less than 105.00% of the Threshold Price.

SEMI-ANNUAL INTEREST PAYMENTS —The notes will pay interest on a semi-annual basis in arrears at the % on each Interest Payment Date, including the Maturity Date, based on a 30/360 adjusted day count convention. The yield on the notes may be less than the overall return you would receive from our conventional fixed income securities with a similar maturity.

RETURN LINKED TO THE PERFORMANCE OF THE REFERENCE STOCK — The return on the notes is linked to the performance of the common stock of JPMorgan Chase & Co. as described herein. *For more information on the Reference Stock, please see “The Reference Stock” in this pricing supplement.*

Selected Risk Considerations

An investment in the notes involves significant risks. Investing in the notes is not equivalent to investing directly in the Reference Stock. In addition to these selected risk considerations, you should review the “Risk Factors” sections of the accompanying prospectus supplement and prospectus.

YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS — The return on the notes is linked to the performance of the Reference Stock and will depend on whether, and the extent to which, the Final Price is greater than the Threshold Price. Because the Issue Price is 105.00% of the Face Amount, excluding interest payments, the notes will not provide for any positive return if the Final Price on each Valuation Date is equal to or less than 105.00% of the Threshold Price. If the Final Price on each Valuation Date is equal to or less than the Threshold Price, you will receive only the Face Amount of the notes per \$1,000 Face Amount of notes, resulting in a loss of approximately 4.76% of your initial investment.

YOU MAY NOT RECEIVE MORE THAN THE FACE AMOUNT OF NOTES PLUS INTEREST PAYMENTS — The return on the notes is linked to the performance of the Reference Stock. If you hold the securities to maturity and the Final Price on each Valuation Date is equal to or less than the Threshold Price, you will not receive more than the Face Amount per \$1,000 Face Amount of notes *plus* any accrued but unpaid interest.

YOU WILL NOT PARTICIPATE IN THE FULL APPRECIATION OF THE REFERENCE STOCK — Even if the Final Price on one or more Valuation Dates is greater than the Threshold Price, the portion of the payment at maturity that reflects the Final Price on such Valuation Dates will reflect only the appreciation of the Reference Stock on such Valuation Dates in excess of the Threshold Price. For example, assuming a Threshold Price of 113% of the Initial Price, if the applicable Final Price for all Valuation Dates were equal to 141.25% of the Initial Price, the payment on the notes would be only \$1,250 per \$1,000 Face Amount of notes for a return of 19.05% (calculated based on the Issue Price of 105.00% of the Face Amount), even though the Reference Stock appreciated 41.25% from the Initial Price.

THE INITIAL PRICE AND THRESHOLD PRICE WILL NOT BE DETERMINED UNTIL AFTER THE TRADING DAY IMMEDIATELY FOLLOWING THE PRICING DATE — Because the Initial Price will be the Adjusted VWAP of one share of the Reference Stock on the trading day immediately following the Pricing Date, the Initial Price will not be determined until after that trading day. Accordingly, you will not know the Initial Price or the Threshold Price, which will be % of the Initial Price, until after the Pricing Date. The Adjusted VWAP of one share of the Reference Stock may increase or decrease during the trading day immediately following the Pricing Date, and there is no assurance that the Initial Price will be similar to or less than the Adjusted VWAP of one share of the Reference Stock on the Pricing Date. In addition, we or our affiliates expect to hedge our obligations under the notes in connection with the sale of the notes, including by purchasing shares of the Reference Stock and/or entering

into derivatives linked to the Reference Stock during that trading day. Your return on the notes may be adversely affected by any increase in the Adjusted VWAP of one share of the Reference Stock during the trading day immediately following the Pricing Date, which would result in a higher Initial Price and higher Threshold Price for the notes.

THE ALTERNATIVE SETTLEMENT AMOUNT IS LINKED TO THE ADJUSTED VWAP OF ONE SHARE OF THE REFERENCE STOCK — The Alternative Settlement Amount for each Valuation Date is calculated by reference to the Adjusted VWAP of one share of the Reference Stock on that Valuation Date and not by reference to the closing price of one share of the Reference Stock on that Valuation Date. The closing price of one share of the Reference Stock may vary significantly from its Adjusted VWAP. Accordingly, if the Adjusted VWAP of one share of the Reference Stock is less than its closing price on the relevant Valuation Date, the payment at maturity (if it is based on the Alternative Settlement Amount in respect of any Valuation Date) will be less than it would have been if the Alternative Settlement Amount were calculated by reference to the closing price of the Reference Stock on the relevant Valuation Date.

THE NOTES ARE SUBJECT TO THE CREDIT OF DEUTSCHE BANK AG — The notes are senior unsecured obligations of Deutsche Bank AG and are not, either directly or indirectly, an obligation of any third party. Any payment(s) to be made on the notes depends on the ability of Deutsche Bank AG to satisfy its obligations as they become due. An actual or anticipated downgrade in Deutsche Bank AG's credit rating or increase in the credit

spreads charged by the market for taking Deutsche Bank AG's credit risk will likely have an adverse effect on the value of the notes. As a result, the actual and perceived creditworthiness of Deutsche Bank AG will affect the value of the notes and, in the event Deutsche Bank AG were to default on its obligations or become subject to a Resolution Measure, you might not receive any amount(s) owed to you under the terms of the notes and you could lose your entire investment.

The NOTES May Be Written Down, Be CONVERTED Into Ordinary Shares or Other Instruments of Ownership or Become Subject to Other Resolution Measures. You May Lose Some or All of Your Investment If Any Such Measure Becomes Applicable to US — Pursuant to the SRM Regulation, the Resolution Act and other applicable rules and regulations described above under “Resolution Measures and Deemed Agreement,” the notes are subject to the powers exercised by the competent resolution authority to impose Resolution Measures on us, which may include: writing down, including to zero, any claim for payment on the notes; converting the notes into ordinary shares of (i) the Issuer, (ii) any group entity or (iii) any bridge bank or other instruments of ownership of such entities qualifying as common equity tier 1 capital; or applying any other resolution measure including, but not limited to, transferring the notes to another entity, amending, modifying or varying the terms and conditions of the notes or cancelling the notes. The competent resolution authority may apply Resolution Measures individually or in any combination.

The German law on the mechanism for the resolution of banks of November 2, 2015 (*Abwicklungsmechanismengesetz*, or the “**Resolution Mechanism Act**”) provides that, in a German insolvency proceeding of the Issuer, certain specifically defined senior unsecured debt instruments would rank junior to, without constituting subordinated debt, all other outstanding unsecured unsubordinated obligations of the Issuer and be satisfied only if all such other senior unsecured obligations of the Issuer have been paid in full. This prioritization would also be given effect if Resolution Measures are imposed on the Issuer, so that obligations under debt instruments that rank junior in insolvency as described above would be written down or converted into common equity tier 1 instruments *before* any other senior unsecured obligations of the Issuer are written down converted. A large portion of our liabilities consist of senior unsecured obligations that either fall outside the statutory definition of debt instruments that rank junior to other senior unsecured obligations according to the Resolution Mechanism Act or are expressly exempted from such definition.

Among those unsecured unsubordinated obligations that are expressly exempted are money market instruments and senior unsecured debt instruments whose terms provide that (i) the repayment or the amount of the repayment depends on the occurrence or non-occurrence of an event which is uncertain at the point in time when the senior unsecured debt instruments are issued or is settled in a way other than by monetary payment, or (ii) the payment of interest or the amount of the interest payments depends on the occurrence or non-occurrence of an event which is uncertain at the point in time when the senior unsecured debt instruments are issued unless the payment of interest or the amount of the interest payments solely depends on a fixed or floating reference interest rate and is settled by monetary payment. This order of priority introduced by the Resolution Mechanism Act would apply in German insolvency proceedings instituted, or when Resolution Measures are imposed, on or after January 1, 2017 with effect for debt instruments of the Issuer outstanding at that time. In a German insolvency proceeding or in the event of the imposition of Resolution Measures with respect to the Issuer, the competent regulatory authority or court would determine which of our senior debt securities issued under the prospectus have the terms described in clauses (i) or (ii) above, referred to herein as the “**Structured Debt Securities**,” and which do not, referred to herein as the “**Non-Structured Debt Securities**.” We expect the notes offered herein to be classified as Structured Debt Securities, but the competent regulatory authority or

court may classify the notes differently. In a German insolvency proceeding or in the event of the imposition of Resolution Measures with respect to the Issuer, the Structured Debt Securities are expected to be among the unsecured unsubordinated obligations that would bear losses after the Non-Structured Debt Securities as described above. **Nevertheless, you may lose some or all of your investment in the notes if a Resolution Measure becomes applicable to us.** Imposition of a Resolution Measure would likely occur if we become, or are deemed by the competent supervisory authority to have become, “non-viable” (as defined under the then applicable law) and are unable to continue our regulated banking activities without a Resolution Measure becoming applicable to us. The Bank Recovery and Resolution Directive and the Resolution Act are intended to eliminate the need for public support of troubled banks, and you should be aware that public support, if any, would only potentially be used by the competent supervisory authority as a last resort after having assessed and exploited, to the maximum extent practicable, the resolution tools, including the bail-in tool.

By acquiring the notes, you would have no claim or other right against us arising out of any Resolution Measure and we would have no obligation to make payments under the notes following the imposition of a Resolution Measure. In particular, the imposition of any Resolution Measure will not constitute a default or an event of default under the notes, under the Indenture or for the purposes of, but only to the fullest extent permitted by, the Trust

PS-11

Indenture Act. Furthermore, because the notes are subject to any Resolution Measure, secondary market trading in the notes may not follow the trading behavior associated with similar types of securities issued by other financial institutions which may be or have been subject to a Resolution Measure.

In addition, by your acquisition of the notes, you waive, to the fullest extent permitted by the Trust Indenture Act and applicable law, any and all claims against the trustee and the indenture agents for, agree not to initiate a suit against the trustee or the indenture agents in respect of, and agree that the trustee and the indenture agents will not be liable for, any action that the trustee or the indenture agents take, or abstain from taking, in either case in accordance with the imposition of a Resolution Measure by the competent resolution authority with respect to the notes. **Accordingly, you may have limited or circumscribed rights to challenge any decision of the competent resolution authority to impose any Resolution Measure.**

THE ISSUER'S ESTIMATED VALUE OF THE NOTES ON THE PRICING DATE WILL BE LESS THAN THE ISSUE PRICE OF THE NOTES — The Issuer's estimated value of the notes on the Pricing Date (as disclosed on the cover of this pricing supplement) is less than the Issue Price of the notes. The difference between the Issue Price and the Issuer's estimated value of the notes on the Pricing Date is due to the inclusion in the Issue Price of the agent's commissions, if any, and the cost of hedging our obligations under the notes through one or more of our affiliates. Such hedging cost includes our or our affiliates' expected cost of providing such hedge, as well as the profit we or our affiliates expect to realize in consideration for assuming the risks inherent in providing such hedge. The Issuer's estimated value of the notes is determined by reference to an internal funding rate and our pricing models. The internal funding rate is typically lower than the rate we would pay when we issue conventional debt securities on equivalent terms. This difference in funding rate, as well as the agent's commissions, if any, and the estimated cost of hedging our obligations under the notes, reduces the economic terms of the notes to you and is expected to adversely affect the price at which you may be able to sell the notes in any secondary market. In addition, our internal pricing models are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect. If at any time a third party dealer were to quote a price to purchase your notes or otherwise value your notes, that price or value may differ materially from the estimated value of the notes determined by reference to our internal funding rate and pricing models. This difference is due to, among other things, any difference in funding rates, pricing models or assumptions used by any dealer who may purchase the notes in the secondary market.

INVESTING IN THE NOTES IS NOT THE SAME AS INVESTING IN THE REFERENCE STOCK — The return on the notes may not reflect the return you would have realized if you had directly invested in the Reference Stock. For instance, you will not receive a cash payment at maturity that is more than the Face Amount per \$1,000 Face Amount of notes (excluding accrued but unpaid interest) unless the Final Price of the Reference Stock on at least one Valuation Date is greater than the Threshold Price.

IF THE PRICE OF THE REFERENCE STOCK CHANGES, THE VALUE OF YOUR NOTES MAY NOT CHANGE IN THE SAME MANNER — Your notes may trade quite differently from the price of the Reference Stock. Changes in the price of the Reference Stock may not result in comparable changes in the value of your notes.

NO DIVIDEND PAYMENTS OR VOTING RIGHTS — As a holder of the notes, you will not have any voting rights or rights to receive cash dividends or other distributions or other rights that holders of the Reference Stock

would have.

ANTI-DILUTION PROTECTION IS LIMITED AND THE CALCULATION AGENT MAY MAKE ADJUSTMENTS IN ADDITION TO, OR THAT DIFFER FROM, THOSE SET FORTH IN THE THIS PRICING SUPPLEMENT — The calculation agent will make adjustments to the Stock Adjustment Factor, which will initially be set at 1.0, for certain corporate events affecting the Reference Stock. The calculation agent is not required, however, to make such adjustments in response to all corporate events that could affect the Reference Stock, including if the Reference Stock Issuer or another party makes a partial tender or partial exchange offer for the Reference Stock. If such an event occurs that does not require the calculation agent to make an adjustment, the value of the notes may be materially and adversely affected. In addition, you should be aware that the calculation agent may, at its sole discretion, make adjustments to the Stock Adjustment Factor or any other terms of the notes that are in addition to, or that differ from, those described in the this pricing supplement to reflect changes occurring in relation to the Reference Stock or any other security received in a reorganization event in circumstances where the calculation agent determines that it is appropriate to reflect those changes to ensure an equitable result. Any alterations to the specified anti-dilution adjustments for the Reference Stock or any other security received in a Reorganization Event may be materially adverse to investors in the notes. You should read “Description of the Notes — Anti-

PS-12

Dilution Adjustments” in this pricing supplement in order to understand the adjustments that may be made to the notes.

YOU MAY RECEIVE A LESSER AMOUNT OF CASH AT MATURITY IF, OVER THE TERM OF THE NOTES, THE REFERENCE STOCK ISSUER FAILS TO PAY A REGULAR CASH DIVIDEND OR PAYS A REGULAR CASH DIVIDEND THAT IS LESS THAN THE BASE DIVIDEND — In calculating the payment due to investors, the calculation agent will take into account any regular cash dividend payment (including no dividend payment) by the Reference Stock Issuer that is either greater or less than the Base Dividend. Consequently, if for any Dividend Period (as defined below) the Reference Stock Issuer pays either no regular cash dividend or a regular cash dividend that is less than the Base Dividend, the calculation agent will reduce the Stock Adjustment Factor, which may in turn reduce the amount of cash that you will receive at maturity.

SINGLE STOCK RISK — The price of the Reference Stock can rise or fall sharply due to factors specific to the Reference Stock and its issuer, such as stock price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock market volatility and levels, interest rates and economic and political conditions. For additional information about the Reference Stock and its issuer, please see “The Reference Stock” in this pricing supplement and such issuer’s SEC filings referred to in that section.

THERE IS NO AFFILIATION BETWEEN THE REFERENCE STOCK ISSUER AND US AND WE HAVE NOT PARTICIPATED IN THE PREPARATION OF, OR VERIFIED, ANY INFORMATION ABOUT THE REFERENCE STOCK OR THE REFERENCE STOCK ISSUER — We are not affiliated with the Reference Stock Issuer. However, we or our affiliates may currently, or from time to time in the future, engage in business with the Reference Stock Issuer, including extending loans to, making equity investments in, acting as underwriter in connection with future offerings of the Reference Stock by, or providing advisory services (including merger and acquisition advisory services) to, such issuer. In the course of this business, we or our affiliates may acquire non-public information about the Reference Stock Issuer and we will not disclose any such information to you. Nevertheless, neither we nor any of our affiliates have participated in the preparation of, or verified, any information about the Reference Stock or the Reference Stock Issuer. You, as an investor in the notes, should make your own investigation into the Reference Stock and the Reference Stock Issuer. The Reference Stock Issuer is not involved in the notes offered hereby in any way and has no obligation of any sort with respect to your notes. The Reference Stock Issuer has no obligation to take your interests into consideration for any reason, including when taking any corporate actions that would require the calculation agent to adjust the Stock Adjustment Factor, which may adversely affect the value of your notes.

PAST PERFORMANCE OF THE REFERENCE STOCK IS NO GUIDE TO FUTURE PERFORMANCE — The actual performance of the Reference Stock over the term of the notes may bear little relation to the historical VWAPs of the Reference Stock and/or the hypothetical examples set forth elsewhere in this pricing supplement. We cannot predict the future performance of the Reference Stock or whether the performance of the Reference Stock will result in the return of any of your investment.

ASSUMING NO CHANGES IN MARKET CONDITIONS AND OTHER RELEVANT FACTORS, THE PRICE YOU MAY RECEIVE FOR YOUR NOTES IN SECONDARY MARKET TRANSACTIONS WOULD GENERALLY BE LOWER THAN BOTH THE ISSUE PRICE AND THE ISSUER’S ESTIMATED

VALUE OF THE NOTES ON THE PRICING DATE — While the payment(s) on the notes described in this pricing supplement is based on the full Face Amount of notes, the Issuer’s estimated value of the notes on the Pricing Date (as disclosed on the cover of this pricing supplement) is less than the Issue Price of the notes. The Issuer’s estimated value of the notes on the Pricing Date does not represent the price at which we or any of our affiliates would be willing to purchase your notes in the secondary market at any time. Assuming no changes in market conditions or our creditworthiness and other relevant factors, the price, if any, at which we or our affiliates would be willing to purchase the notes from you in secondary market transactions, if at all, would generally be lower than both the Issue Price and the Issuer’s estimated value of the notes on the Pricing Date. Our purchase price, if any, in secondary market transactions would be based on the estimated value of the notes determined by reference to (i) the then-prevailing internal funding rate (adjusted by a spread) or another appropriate measure of our cost of funds and (ii) our pricing models at that time, less a bid spread determined after taking into account the size of the repurchase, the nature of the assets underlying the notes and then-prevailing market conditions. The price we report to financial reporting services would generally be determined on the same basis.

In addition to the factors discussed above, the value of the notes and our purchase price in secondary market transactions after the Pricing Date, if any, will vary based on many economic and market factors, including our

PS-13

creditworthiness, and cannot be predicted with accuracy. These changes may adversely affect the value of your notes, including the price you may receive in any secondary market transactions. Any sale prior to the Maturity Date could result in a substantial loss to you. The notes are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.

THE NOTES WILL NOT BE LISTED AND THERE WILL LIKELY BE LIMITED LIQUIDITY — The notes will not be listed on any securities exchange. There may be little or no secondary market for the notes. We or our affiliates intend to act as market makers for the notes but are not required to do so and may cease